Gary Shelton

617 total citations
14 papers, 477 citations indexed

About

Gary Shelton is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Dermatology. According to data from OpenAlex, Gary Shelton has authored 14 papers receiving a total of 477 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 3 papers in Dermatology. Recurrent topics in Gary Shelton's work include Prostate Cancer Treatment and Research (6 papers), Cancer Treatment and Pharmacology (6 papers) and Chemotherapy-related skin toxicity (3 papers). Gary Shelton is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), Cancer Treatment and Pharmacology (6 papers) and Chemotherapy-related skin toxicity (3 papers). Gary Shelton collaborates with scholars based in United States and Canada. Gary Shelton's co-authors include Daniel P. Petrylak, Mitchell C. Benson, Nancy Zuech, Emilia Bagiella, Timothy Judge, Charles Pfaff, Robert B. MacArthur, Ihor S. Sawczuk, Carl A. Olsson and Daniel F. Heitjan and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Journal of Urology.

In The Last Decade

Gary Shelton

14 papers receiving 457 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gary Shelton United States	8	343	200	93	89	66	14	477
M.C. Cox United States	10	177 0.5×	180 0.9×	74 0.8×	91 1.0×	50 0.8×	23	429
Charles R. Sikes United States	10	262 0.8×	175 0.9×	72 0.8×	122 1.4×	13 0.2×	12	402
Karen Giselle Chee United States	7	163 0.5×	182 0.9×	36 0.4×	102 1.1×	27 0.4×	9	380
Spyridon Sideris Belgium	11	379 1.1×	158 0.8×	154 1.7×	65 0.7×	18 0.3×	27	504
Eva Markert Germany	9	167 0.5×	181 0.9×	61 0.7×	82 0.9×	29 0.4×	20	405
Lea Latham Italy	9	173 0.5×	163 0.8×	84 0.9×	113 1.3×	36 0.5×	17	401
Begoña Pérez‐Valderrama Spain	13	220 0.6×	148 0.7×	106 1.1×	155 1.7×	15 0.2×	50	405
Flavio Mavignier Cárcano Brazil	12	193 0.6×	89 0.4×	101 1.1×	166 1.9×	18 0.3×	34	418
BC Lembersky United States	8	169 0.5×	295 1.5×	160 1.7×	47 0.5×	22 0.3×	14	442
Paloma Martín-Martorell Spain	11	190 0.6×	279 1.4×	52 0.6×	82 0.9×	10 0.2×	30	426

Countries citing papers authored by Gary Shelton

Since Specialization

Citations

This map shows the geographic impact of Gary Shelton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Shelton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Shelton more than expected).

Fields of papers citing papers by Gary Shelton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Shelton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Shelton. The network helps show where Gary Shelton may publish in the future.

Co-authorship network of co-authors of Gary Shelton

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Shelton. A scholar is included among the top collaborators of Gary Shelton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Shelton. Gary Shelton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

1.

Wiley, Kathleen E., et al.. (2020). Skin Toxicity: Clinical Summary of the ONS Guidelines™ for Cancer Treatment–Related Skin Toxicity. Clinical journal of oncology nursing. 24(5). 561–565. 7 indexed citations

2.

Williams, Loretta A., Pamela Ginex, Kathryn Ciccolini, et al.. (2020). ONS Guidelines™ for Cancer Treatment–Related Skin Toxicity. Oncology nursing forum. 47(5). 539–556. 14 indexed citations

3.

Doyle, Seán, et al.. (2020). Making the case for virtual competency-based education. Higher Education Skills and Work-based Learning. 11(1). 282–295. 5 indexed citations

4.

Wu, Shengyang, et al.. (2018). Early Palliative Care for Patients With Brain Metastases Decreases Inpatient Admissions and Need for Imaging Studies. American Journal of Hospice and Palliative Medicine®. 35(8). 1069–1075. 13 indexed citations

5.

Boorjian, Stephen A., Matthew I. Milowsky, Martin Albert, et al.. (2007). Phase 1/2 Clinical Trial of Interferon α2b and Weekly Liposome-encapsulated All-trans Retinoic Acid in Patients With Advanced Renal Cell Carcinoma. Journal of Immunotherapy. 30(6). 655–662. 36 indexed citations

6.

Petrylak, Daniel P., Supriya G. Mohile, Gary Shelton, et al.. (2006). Pharmacokinetics (PK), safety and tolerability of atrasentan (ABT-627, ATN) in combination with docetaxel (DOC) in men with hormone refractory prostate cancer (HRPC). Journal of Clinical Oncology. 24(18_suppl). 14512–14512. 2 indexed citations

7.

Moss, Rachel, Gary Shelton, J Melia, Supriya G. Mohile, & Daniel P. Petrylak. (2006). A phase I open-label, dose escalation study to determine the maximum tolerated dose and to evaluate the safety profile of lenalidomide with every three week docetaxel in subjects with androgen independent prostate cancer. Journal of Clinical Oncology. 24(18_suppl). 14618–14618. 1 indexed citations

8.

Hovey, Elizabeth, et al.. (2004). Phase I/II study of docetaxel (D), gemcitabine (G), Carboplatin (C) in poor prognosis and previously treated patients (pts) with urothelial carcinoma (UTC). Journal of Clinical Oncology. 22(14_suppl). 4580–4580. 2 indexed citations

9.

Hovey, Elizabeth, et al.. (2004). Phase I/II study of docetaxel (D), gemcitabine (G), Carboplatin (C) in poor prognosis and previously treated patients (pts) with urothelial carcinoma (UTC). Journal of Clinical Oncology. 22(14_suppl). 4580–4580. 4 indexed citations

10.

Goldberg, Jonathan S., Matthew I. Milowsky, Lorraine J. Gudas, et al.. (2002). Phase I trial of interferon α2b and liposome‐encapsulated all‐trans retinoic acid in the treatment of patients with advanced renal cell carcinoma. Cancer. 95(6). 1220–1227. 19 indexed citations

11.

Weitzman, Aaron, Gary Shelton, Nancy Zuech, et al.. (2000). DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER. The Journal of Urology. 163(3). 834–837. 50 indexed citations

12.

Shelton, Gary, Nancy Zuech, Cindy E. Owen, et al.. (2000). DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER. The Journal of Urology. 834–834. 1 indexed citations

13.

Petrylak, Daniel P., Robert B. MacArthur, Jacqueline M. O’Connor, et al.. (1999). Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.. PubMed. 26(5 Suppl 17). 28–33. 74 indexed citations

14.

Petrylak, Daniel P., Robert B. MacArthur, John F. O’Connor, et al.. (1999). Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer. Journal of Clinical Oncology. 17(3). 958–958. 249 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact